Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study

Fulvestrant Revisited: Efficacy and Safety of the 500-mg Dose

(2011) Anthony Howell et al.   Clinical Breast Cancer

Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)

(2010) S. Ohno et al.   ANNALS OF ONCOLOGY

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2)

(2010) Kathleen I. Pritchard et al.   BREAST CANCER RESEARCH AND TREATMENT

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

(2010) Angelo Di Leo et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study

(2009) John F.R. Robertson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

(2008) Robert J. Paridaens et al.   JOURNAL OF CLINICAL ONCOLOGY